Clinical Trial Search

Primary: To Assess the Impact of an Educational Lecture on Knowledge About Keloid Scars by Comparing Mean Scores Between Knowledge Assessment Questionnaires Administered Before…

Primary: Change in Keloid Surface Area — 0.455; -0.039 cm2

Primary: Change in Patient and Observer Scar Assessment Scale (POSAS) Score From Baseline to Final Visit — -20; -20.6 score on a scale

Primary: Change in Lesion Volume — 40; 42; 32 Percent Change

Primary: Percentage of Subjects With Confirmed Keloid Formation at Treated vs. Untreated Lesions at 24 Weeks — 92.9; 85.7 percentage of participants

Primary: Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores — 23.29; 24.11; 21.33; 18.53 Units on a scale — p=0.87

Primary: Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores — 13.3; 17.7; 15.9; 17.1 Units on a scale — p=0.078

Primary: MMSS for Scar Halves Treated — 8.4; 8.7 score on a scale

Primary: The Primary Purpose of This Study Will be to Gain Preliminary Safety Experience With Apligraf in the Keloid Indication. The Number of Participants Experiencing AEs is…

Primary: Cosmetic Outcome — 7.4; 6.6; 6.3; 6.00 score on a scale

Primary: Change in Scar Pliability Between the Treated and Control Incision Sites as Measured by Skin Elasticity at 6 Months Compared to Baseline

Primary: Post-operative Scarring - Erythema — 1.67; 1.70; 1.50; 1.65 score on a scale — p=0.48

Primary: Physician Global Assessment Using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS) — 4.00; 4.68; 4.61; 4.86 units on scale…

Primary: Patient and Observer Scar Assessment Scale (POSAS)- Patient Scores 12M — 1.09; 1.22; 1.3; 1.87 score on a scale

Primary: Improvement of Surgical Scars at 12 Months Compared to Baseline (Pre-treatment) as Evaluated by 3 Independent Blinded Reviewers Using the General Aesthetic Improvement…

Primary: Number Participants With Hypertropic Scarring, Keloid Formation, Hyper- or Hypopigmentation in Patients With Fitzpatrick Skin Types IV, V, and VI Receiving Nasolabial…

Primary: Visual Analogue Scale (VAS) — 2.90; 3.29 score on a scale

Primary: Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) — 0; 50 Percentage reporting improvement

Primary: Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS) — -9.5; -8.9 score on a scale

Primary: Patient Observer Scar Assessment Scale (POSAS) — 17.69; 11.2; 15.2; 11.4 units on a scale — p=0.019

Primary: Modified Manchester Scar Scale (MMSS) Score — 8; 11.5 score on a scale

Primary: Photography- Independent Scar Assessment Panel

Primary: Improvement in Surgical Scar of Treatment (532nm KTP Laser) and Active Control (595nm PDL) Treatment Arms. — 2.0; 1.5 score on a scale

Primary: Expert Panel Scar Assessment Score at Week 12 — 36.6; 51.4 millimeter — p=<0.001

Primary: Physician Observer Scar Assessment Score at Week 24 — 0.0; -0.5; 0.8; -0.3 units on a scale — p=1.000

Primary: Photographic Evaluation of Scar Clearance — 1.82 score on a scale

Primary: Mean Change From Baseline in Erythema — -1.687; 5.730 units on a scale

Primary: Visual Analogue Scale (VAS) — 3.78; 5.58 Units on a scale

Primary: Percentage Change in Total AKN Lesions From Baseline to Week 16. — 49 percentage of lesion count reduction

Primary: Change in Vectra Measured Length V1 (Month 0)-V2 (Month 3) for Original Group; Visit 3 (Month 6) to Visit 4 (Month 9) for Crossover Group — 0.10; 0.03 mm